[West syndrome--new therapeutic approach]

Area of Science:

• Epilepsy and Neurological Disorders
• Pediatric Neurology
• Pharmacology and Therapeutics

Context:

• West syndrome (WS) is an age-dependent epileptic encephalopathy with diverse etiologies and lesion types.
• WS is often refractory to conventional antiepileptic drugs, necessitating specialized treatment approaches.
• Current treatment options like adrenocorticotropic hormone (ACTH) and vigabatrin have efficacy but also associated risks.

Purpose:

• To compare the risk-benefit profiles of vigabatrin and ACTH in the management of West syndrome.
• To identify optimal patient subgroups for the use of vigabatrin and ACTH.
• To inform treatment decisions for refractory epilepsy in West syndrome.

Summary:

• Adrenocorticotropic hormone (ACTH) and corticosteroids have been used for decades, with variable efficacy and significant side effects.
• Vigabatrin shows promise, particularly in pediatric cases, with potential for reversibility of visual field defects.
• Newer antiepileptic drugs like lamotrigine, topiramate, felbamate, and zonisamide also demonstrate efficacy in treatment-resistant WS.

Impact:

• Provides a framework for assessing the optimal use of vigabatrin and ACTH in West syndrome.
• Aims to improve treatment outcomes and minimize adverse effects in patients with this challenging epilepsy.
• Contributes to the evidence base for managing refractory infantile spasms and related neurological conditions.